Abstract:

Cancer-related neuropathic pain （CRNP） is a common type of pain among cancer patients， significantly impacting their quality of life. To standardize the clinical management of CRNP， the Chinese Society of Clinical Oncology-Supportive Care and Rehabilitation Committee organized experts from related fields to develop this consensus based on the GRADE evidence grading system. The consensus clarifies the definition and etiological classification of CRNP （cancer-induced， anticancer treatment-induced， and oncology multimorbidity-related）， systematically elaborates on the screening， diagnosis， and assessment processes of CRNP， recommends the use of scales such as DN4 and LANSS for screening， and confirms the diagnosis based on the NeuPSIG grading system. In terms of treatment， the consensus recommends selecting first-line drugs such as calcium channel modulators， tricyclic antidepressants， and serotonin-norepinephrine reuptake inhibitors based on the etiology， and emphasizes multimodal interventions such as combination therapy， local therapy， minimally invasive intervention， and physical therapy. Additionally， priority should be given to comprehensive patient education， evidence-informed psychological support， integration of traditional medicine and structured long-term follow-up management. This consensus provides evidence-based basis and practical guidance for the individualized and multidisciplinary comprehensive management of CRNP.

Key words: Cancer pain, Neuralgia, Diagnosis, Therapy, Expert consensus